Category Archives: National Healthcare


Employer-Based Health Care – All Cons, No Pros

Since the beginning of the debates around the Affordable Care Act (ACA), there’s been a relatively muted on-going conversation about the value of the employer based health insurance model. It has, however, never really come to the fore as the ACA never seriously engaged with the idea of canning the whole system and starting fresh […]

Read More

Posted in Health reform, National Healthcare; Tagged: .


Innovative Solutions for Complex Health Challenges: Our Past, Present, and Future – The O’Neill Institute Retrospective

We are delighted to present the Retrospective for the O’Neill Institute for National and Global Health Law at Georgetown University, Innovative Solutions for Complex Health Challenges: Our Past, Present, and Future.  

Read More

Posted in FCTC, FDA, Global Health, Health reform, Human Rights, National Healthcare, Resources, Tobacco, Trade, WHO; Tagged: , , , , , , , , , , , , , .


US FDA Commissioner Margaret Hamburg to Keynote O’Neill Institute Summer Program on Emerging Issues in Food and Drug Law

The Commissioner of the United States Food and Drug Administration, Margaret Hamburg will provide the keynote address to the O’Neill Institute for National and Global Health Law’s Summer Program on Emerging Issues in Food and Drug Law. Margaret A. Hamburg became the 21st commissioner of food and drugs on May 18, 2009. The second woman […]

Read More

Posted in FDA, Global Health, National Healthcare, Tobacco, Trade, Uncategorized; Tagged: , , , , , .


July 21-25 – US Health Reform – The Affordable Care Act (O’Neill Institute Summer Program with Confirmed Speakers)

The American healthcare system has undergone enormous change in the last few years. At both the federal and state levels, understanding the new landscape introduced by the Affordable Care Act, with its legal intricacies and policy nuance, is paramount to anyone working in this field. This summer, join Georgetown scholars and DC health policy wonks […]

Read More

Posted in Health reform, National Healthcare, Uncategorized; Tagged: , , , , .


July 14-18 – Emerging Issues in Food and Drug Law (O’Neill Institute Summer Program with Confirmed Speakers)

Please join the O’Neill Institute for National and Global Health Law at Georgetown University for a one-week intensive summer institute exploring the domestic and international legal, regulatory, and policy framework shaping the safety and availability of foods and medicines worldwide. The program will cover U.S. domestic law including recent laws and regulations; international regulatory harmonization […]

Read More

Posted in FDA, Global Health, Health reform, National Healthcare, Tobacco, Trade, Uncategorized; Tagged: , , , , .


Five Things About the Affordable Care Act Post Open Enrollment

This post was co-authored by Michael Templeman, Director, New Initiatives at the O’Neill Institute for National and Global Health Law. The first open enrollment period for the Affordable Care Act (ACA), or “Obamacare” officially closed on March 31.  Here are five things to know about the ACA post-open enrollment. 1. Number of Enrollees Has Exceeded […]

Read More

Posted in Health reform, National Healthcare, Uncategorized; Tagged: , , , .


Is obesity the ticket to fighting antibiotic resistance?

Research points to the possibility that taking antibiotics could lead to weight gain. Could this reality be the necessary catalyst to change the way we use antibiotics in general?Antibiotic overuse is a public health crisis. For decades, scientists have supported changing antibiotic prescribing practices in response to the alarming consequences of their overuse – most […]

Read More

Posted in FDA, Global Health, National Healthcare, Uncategorized; Tagged: , .


Do prescription drugs need a message?

The recent controversy surrounding a relatively new blood thinner called Pradaxa (dabigatran) centers not on the drug itself, but on the safety of the drug’s message. Brought to market as a superior product to the long-standing market leader, Coumadin (warfarin), Pradaxa is touted for its ability to treat atrial fibrillation without the inconvenience of frequent […]

Read More

Posted in FDA, National Healthcare;


CVS’s Bold Move: Goodbye Tobacco, Hello Health Care

 This week, the second-largest drugstore chain CVS Caremark Corp. (CVS) announced that it will stop selling tobacco products in its 7,600 pharmacies starting on October 1. The medical and tobacco control advocacy organizations applaud the decision, as it contributes to combatting tobacco consumption in the U.S. and exerts pressure on competitors to do the same. […]

Read More

Posted in Health reform, National Healthcare, Tobacco; Tagged: , , , , , , , , , .


Four things we should probably stop doing in the name of public health in 2014

Within public health, we have many victories to claim. Vaccinations – for example – have been and remain unmitigated successes. Yet, there are many public health interventions that have been instituted and promoted by public health advocates, medical doctors, and various pharmaceutical or medical device companies that have proven to be ineffective at improving health […]

Read More

Posted in Global Health, National Healthcare;


Browse by Category

Browse by Month

2014

April (11), March (11), February (12), January (7)

2013

December (8), November (8), October (15), September (5), August (4), July (8), June (13), May (10), April (8), March (9), February (8), January (3)

2012

December (3), November (3), October (2), August (1), July (6), June (2), May (3), April (3), March (2), February (2), January (4)

2011

December (2), November (2), October (4), September (3), August (5), July (5), June (9)

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.